MS Pharma

active

The proposed project involves an IFC equity investment of up US$ 50 million in MS Pharma Ventures Holding W.L.L. (“MS-Pharma” or “the group”), a Jordan based generic pharmaceutical manufacturer and distributor across the Middle East and North Africa (MENA) region.   The investment will allow MS-Pharma to continue increasing its geographical reach in the region mainly via mergers and acquisitions of manufacturing assets in new markets or construction of new facilities (Saudi Arabia). Short-term plans include upgrading the MS-Pharma injectable plant (MSI) in Jordan and MS Pharma Injectable plant in Turkey (acquired in 2012 and 2016 respectively), expanding the El Kendi manufacturing facility in Algeria to double production capacity, and pursue acquisition of product portfolio/marketing authorizations to accelerate market entry (Egypt).  In Saudi Arabia the group has acquired in the private market an area, within a pharmacological industrial park, where it plans to build a production facility and worker accommodations. In Algeria, the group, via the controlled El Kendi Pharma Manufacturing, will expand its production by building, within the same property where the existing plant is located, a new 4-story facility with a 1,750-m2 footprint and a total floor space on 7,000 m2.  MS-Pharma activities date back to 1989 when the first company, United Pharmaceutical (UNP), and its production plant was established in Amman, Jordan.  The group, a limited liability company incorporated in the Kingdom of Bahrain, specializes in generic pharmaceutical products for five therapeutic areas: cardiology, central nervous system, respiratory, oncology and anti-inflammatory.  It consolidates manufacture and trade of both branded and unbranded products in 11 countries across MENA.